The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Prime-Boost Interval Matters: A Randomized Phase 1 Study to Identify the Minimum Interval Necessary to Observe the H5 DNA Influenza Vaccine Priming Effect
Open accessAbstract
BACKGROUND: H5 DNA priming was previously shown to improve the antibody response to influenza A(H5N1) monovalent inactivated vaccine (MIV) among individuals for whom there was a 24-week interval between prime and boost receipt. This study defines the shortest prime-boost interval associated with an improved response to MIV. METHODS: We administered H5 DNA followed by MIV at intervals of 4, 8, 12, 16, or 24 weeks and compared responses to that of 2 doses of MIV (prime-boost interval, 24 weeks). RESULTS: H5 DNA priming with an MIV boost ≥12 weeks later showed an improved response, with a positive hemagglutination inhibition (HAI) titer in 91% of recipients (geometric mean titer [GMT], 141-206), compared with 55%-70% of recipients with an H5 DNA and MIV prime-boost interval of ≤8 weeks (GMT, 51-70) and 44% with an MIV-MIV prime-boost interval of 24 weeks (GMT, 27). CONCLUSION: H5 DNA priming enhances antibody responses after an MIV boost when the prime-boost interval is 12-24 weeks. Clinical Trials Registration. NCT01086657.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine
Treanor, J. J., Campbell, J. D., Zangwill, K. M., Rowe, T., & Wolff, M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055778 · Cited by 698
Induction of Broadly Neutralizing H1N1 Influenza Antibodies by Vaccination
Wei, C., Boyington, J. C., McTamney, P. M., Kong, W., Pearce, M. B., Xu, L., Andersen, H., Rao, S. S., Tumpey, T. M., Yang, Z., et al. (2010) · Science · doi:10.1126/science.1192517 · Cited by 337
Self-citationCatanzaro, A. T., Koup, R. A., Roederer, M., Bailer, R. T., Enama, M. E., Moodie, Z., Gu, L., Martin, J. E., Novik, L., Chakrabarti, B. K., et al. (2006) · The Journal of Infectious Diseases · doi:10.1086/509258 · Cited by 319
Self-citationA DNA Vaccine for Ebola Virus Is Safe and Immunogenic in a Phase I Clinical Trial
Martin, J. E., Sullivan, N. J., Enama, M. E., et al. (2006) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00162-06 · Cited by 235
Self-citationWei, C., Boyington, J. C., Dai, K., Houser, K. V., Pearce, M. B., Kong, W., Yang, Z., Tumpey, T. M., & Nabel, G. J. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000799 · Cited by 232
Self-citationDNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials
Ledgerwood, J. E., Wei, C., Hu, Z., Gordon, I. J., Enama, M. E., Hendel, C. S., McTamney, P. M., Pearce, M. B., Yassine, H. M., Boyington, J. C., et al. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70240-7 · Cited by 188
Self-citationStephenson, I., Wood, J., Nicholson, K. G., et al. (2004) · Virus Research · doi:10.1016/j.virusres.2004.02.019 · Cited by 187
Ledgerwood, J. E., Pierson, T. C., Hubka, S. A., Desai, N., Rucker, S., Gordon, I. J., Enama, M. E., Nelson, S., Nason, M., Gu, W., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir054 · Cited by 156
Self-citationPhase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine
Catanzaro, A. T., Roederer, M., Koup, R. A., Bailer, R. T., Enama, M. E., Nason, M., Martin, J. E., Rucker, S., Andrews, C. A., Gomez, P. L., et al. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.02.050 · Cited by 151
Self-citationWei, C., Xu, L., Kong, W., Shi, W., Canis, K., Stevens, J., Yang, Z., Dell, A., Haslam, S. M., Wilson, I. A., et al. (2008) · Journal of Virology · doi:10.1128/jvi.00187-08 · Cited by 147
Self-citationWu, L., Kong, W., & Nabel, G. J. (2005) · Journal of Virology · doi:10.1128/jvi.79.13.8024-8031.2005 · Cited by 73
Self-citationFlu transmission work is urgent
Kawaoka, Y. (2012) · Nature · doi:10.1038/nature10884 · Cited by 57
Ledgerwood, J. E., & Graham, B. S. (2009) · Human Vaccines · doi:10.4161/hv.8627 · Cited by 32
Self-citationWill Flu Papers Lead to New Research Oversight?
Enserink, M., & Malakoff, D. A. (2012) · Science · doi:10.1126/science.335.6064.20 · Cited by 18
Flagged first, then by citations
Research works printed but not linked: 1
- WHO, Confirmed human cases of avian influenza A(H5N1)
Cited by
Sorted by citations
Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389
Voysey, M., Costa Clemens, S. A., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00432-3 · Cited by 1,119
Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses
Joyce, M. G., Wheatley, A. K., Thomas, P. V., Chuang, G.-Y., Soto, C., Bailer, R. T., Druz, A., Georgiev, I. S., Gillespie, R. A., Kanekiyo, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.043 · Cited by 333
Self-citationBernal, J. L., Andrews, N., Gower, C., Stowe, J., Robertson, C., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · doi:10.1101/2021.03.01.21252652 · Cited by 1,389
“(6) Furthermore, with other vaccines an extended interval between the prime and booster doses typically provides a better immune response to the booster dose.(7, 8) Based on this evidence, the increasing incidence of COVID-19 in the UK and the need to rapidly vaccinate as many vulnerable people as possible, on the 20…”
Background
Metadata
- Authors
- Ledgerwood, J. E., Zephir, K., Hu, Z., Wei, C.-J., Chang, L., Enama, M. E., Hendel, C. S., Sitar, S., Bailer, R. T., Koup, R. A., Mascola, J. R., Nabel, G. J., Graham, B. S., & the VRC 310 Study Team
- Affiliations
- Vaccine Research Center (US)
- National Institutes of Health (US)
- Vaccine Research Center
- Corresponding author
- Ledgerwood, Julie E.
- ORCID
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-04-30
- Volume
- 208
- Issue
- 3
- Pages
- 418-422
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- PMC
- PMC3699006
- OpenAlex
- W2165908776
- Cited by
- 123
- References
- 14
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 8 · 2023: 6 · 2022: 7 · 2021: 13 · 2020: 4 · 2019: 6 · 2018: 12 · 2017: 11 · 2016: 4 · 2015: 25 · 2014: 16 · 2013: 3
- FWCI
- 11.66
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
- Keywords
- H5N1 avian influenza, inactivated influenza vaccine, hemagglutination inhibition, antibody response, vaccine priming
- MeSH terms
- Adolescent, Adult, Antibodies, Viral, Female, Hemagglutination Inhibition Tests, Humans, Immunization, Secondary, Influenza Vaccines, Male, Middle Aged, Time Factors, Vaccines, Inactivated, Hemagglutinin Glycoproteins, Influenza Virus, Vaccines, DNA, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
